Analyst Price Target is C$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Ondine Biomedical in the last 3 months. The average price target is C$0.00, with a high forecast of C$0.00 and a low forecast of C$10,000,000.00. The average price target represents a -100.00% upside from the last price of C$14.00.
Current Consensus is
N/A
The current consensus among 0 investment analysts is to n/a stock in Ondine Biomedical. This rating has held steady since January 2024, when it changed from a Buy consensus rating.
Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.
Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings. We are focused on solutions that address significant needs, are easy to deploy, are environmentally safe, provide substantial public health benefits, and cost a fraction of the infections they target.
Our photodisinfection technology has been used successfully for many years in more than 100,000 patient treatments in hospitals, clinics, and industrial settings across Canada.
Read More
